Savara Revenue

Pharmaceutical Manufacturing • United States, United States, United States • 51-100 Employees

Savara revenue & valuation

Annual revenue	$257,000
Revenue per employee	$3,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$822,400
Total funding	$156,500,000

Key Contacts at Savara

Rick Hawkins

Member Board Of Directors

Stephanie J. Harris

Sr. Director Of Project Management

Theresa L Markey

Senior Director, Head Of Pharmacovigilance And Drug Safety

Tarana Shaghasi

Associate Director Analytical Sciences

Larry Corrigan

Senior Director, Commercial Analytics Lead

Patti Smith M. S.

Senior Director, Head Of North America Regulatory Affairs

Staci Stephens

Regional Business Director-West

Christopher Knecht

Sr. Director, Quality Assurance

Joe Yezza

Regional Business Director - East

Suchi Vajrala

Sr. Director, Project Management

Company overview

Headquarters	United States, United States, United States
Phone number	+15126141848
Website	savarapharma.com
NAICS	3254
SIC	283
Keywords	Drug Delivery, Biotech, Therapeutics, Aerosol, dpi, Biopharma, Rare Disease, Pulmonary, Lung, Respiratory, Dry-Powder, Inhaler
Founded	2007
Employees	51-100
Socials

Savara Email Formats

Savara uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@savarapharma.com), used 91.3% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@savarapharma.com	91.3%
{first name}.{last name}	john.doe@savarapharma.com	4.3%
{first initial}{last name}.{last name}	jdoe.doe@savarapharma.com	2.2%
{first initial}.{second initial}	j.o@savarapharma.com	2.2%

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Director

Vice President

Employees by Department

Savara has 44 employees across 10 departments.

Departments

Number of employees

Funding Data

Explore Savara's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2022-05-22	16	$26,500,000
2024-07-28	14	$100,000,000
2025-04-26	16	$30,000,000

Funding Insights

$156,500,000

Total funding amount

$30,000,000

Most recent funding amount

Number of funding rounds

Savara Tech Stack

Discover the technologies and tools that power Savara's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

HTTP/3

Miscellaneous

Frequently asked questions

Savara is located in United States, United States, US.

You can reach Savara at +15126141848.

Savara generates an estimated annual revenue of $257,000. This revenue figure reflects the company's market position and business performance in its industry.

Savara has an estimated valuation of $822,400. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Savara was founded in 2007, making it 19 years old. The company has established itself as a significant player in its industry over this time.

Savara has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Savara has raised a total of $156,500,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.